Receptor Activating Compounds for Endocrine Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for type-2 diabetes mellitus and obesity, such as GLP-1 analogs and dual GLP-1/GIP analogs, are associated with high risks of adverse events, significant side effects, and high costs, necessitating the development of improved compositions and methods that can effectively modulate GI cell activity and suppress appetite with minimal side effects.
Innovation Solution
The development of compositions that include a delivery medium and specific receptor activating compounds adapted to bind and activate olfactory receptors and free fatty acid receptors, thereby inducing the secretion of endogenous GLP-1, GIP, and PYY, without the undesirable side effects associated with traditional treatments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If GLP-1 analogs are used to treat type-2 diabetes mellitus and obesity, then insulin secretion is increased and appetite is suppressed, but the risk of adverse events and side effects increases significantly
Solution Approach 1:
The patent uses endogenous GLP-1, GIP, and PYY hormones as intermediaries to mediate the therapeutic effect. Instead of administering exogenous GLP-1 analogs directly, the composition uses receptor-activating compounds (such as olfactory receptor agonists and free fatty acid receptor agonists) to stimulate the body's own cells to secrete these hormones naturally, thereby achieving treatment efficacy while avoiding the adverse effects associated with direct GLP-1 analog administration
Solution Approach 2:
The invention enables the body's own gastrointestinal cells to produce and secrete the therapeutic hormones (GLP-1, GIP, PYY) in response to receptor activation by the composition. This self-service mechanism allows the body to regulate its own hormone levels according to physiological needs, avoiding the risk of supraphysiological hormone levels and associated side effects that occur with exogenous GLP-1 analog administration
2Reliability
If traditional GLP-1 analog treatments are administered, then metabolic control is improved, but the cost of treatment increases significantly
Solution Approach 1:
The patent employs receptor-activating compounds (such as volatile organic compounds, fatty acids, and their derivatives) that are generally inexpensive substances. These compounds activate endogenous hormone secretion temporarily, and the effect is short-lived, requiring repeated administration. This approach replaces expensive long-acting GLP-1 analog medications with cheaper, short-acting receptor activators, thereby reducing overall treatment cost while maintaining metabolic control
3Object-affected harmful factors
If receptor activating compounds are used to induce endogenous hormone secretion, then side effects are minimized, but the complexity of the composition increases
Solution Approach 1:
The patent segments the therapeutic approach by targeting different receptors separately - olfactory receptors (ORs), free fatty acid receptors (FFARs), and other specific receptors. Each receptor-activating compound in the composition is designed to activate a specific receptor pathway that leads to hormone secretion. This segmentation allows for modular composition design where different compounds can be combined in various ratios to achieve desired therapeutic effects while minimizing side effects
Solution Approach 2:
The invention creates a composite composition containing multiple receptor-activating compounds (such as olfactory receptor agonists, free fatty acid receptor agonists, and their combinations) along with delivery vehicles. This composite approach leverages the synergistic effects of different compounds acting on different receptors to achieve robust hormone secretion while distributing the potential side effects across multiple pathways, thereby reducing the overall toxicity profile
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compositions effectively increase insulin secretion and suppress appetite, providing a more efficient and safer treatment option for type-2 diabetes mellitus and obesity, while also being administered through various routes including oral, sublingual, and injection.
Implementation Method 1
specific receptor activating compounds adapted to bind and activate olfactory receptors and free fatty acid receptors, thereby inducing the secretion of endogenous GLP-1, GIP, and PYY
Data Source
AI summary
Disclosed herein are compounds and ligands, and compositions formed therewith, that modulate insulin secretion and suppress appetite by activating ectopic olfactory receptors. Also disclosed herein are methods for using the compositions to treat endocrine diseases, such as type-2 diabetes, and disorders, such as abnormal insulin secretion.